Roche Breast Cancer Drug Appears to Greatly Extend Patients’ Lives by ANDREW POLLACK

By ANDREW POLLACK

Perjeta, approved by the F.D.A. in 2012, prolonged median survival time about 16 months in a trial of 808 people with metastatic breast cancer.

Published: September 29, 2014 at 4:00AM

from NYT Business Day http://ift.tt/1mCJi8r

from WordPress http://ift.tt/Yu4GBu

via Hadi Aboukhater